Received tentative approval from the FDA for YUTREPIATM (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) ...
The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...
November is Pulmonary Hypertension Awareness Month, and George Washington University Hospital’s Doctor Mardi Gomberg-Maitland ...
Columnist Colleen Steele took a break from writing after her husband passed away in 2023, but she's ready to keep raising PH awareness.
Pharmacokinetic Results: TX45 demonstrated a potential best-in-class half-life for a long-acting relaxin therapy. Final analysis showed that a single dose of TX45 had approximately 50% subcutaneous ...
In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.
Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant ...
The following is a summary of “Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial,” ...
Therapies that target the prostacyclin pathway hold promise as chronic CTEPH treatment, a meta-analysis of controlled trials ...
A new study by a team of 12 thoracic surgeons at Memorial Sloan Kettering Cancer Center (MSK), published recently in the ...
Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback